Emily Jaksich
Acute Care · Springfield, ORNPI 1336510635
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $357 of the $476 with a category attached, or 75.0%. It is spread thinly across 12 manufacturers, the largest accounting for just 23.4%. Reporting peaked in 2021 at $241 and has fallen 53.8% since, to $112 in 2024.
Across 13 payments — averaging $36.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$112
- Johnson & Johnson$99
- Medtronic$90
- Bristol Myers Squibb$39
- AbbVie$21
- Acorda Therapeutics, Inc$20
- plus $96 from 6 others
What the payments were for
- Speaking & faculty fees$204%
- Food & beverage$35775%
- Education$9921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $112 |
| Johnson & Johnson | 1 | $99 |
| Medtronic | 1 | $90 |
| Bristol Myers Squibb | 2 | $39 |
| AbbVie | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| SK Life Science, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Zogenix Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$112
How this compares
$476 in reported general payments places this provider in the 60th percentile of 105 acute care providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $52,315 |
| Levetiracetam | 36 | $1,260 |
| Atorvastatin Calcium | 31 | $554 |
| Rosuvastatin Calcium | 32 | $469 |
| Sertraline Hcl | 15 | $171 |
| ClopidogrelClopidogrel Bisulfate | 11 | $148 |
| Escitalopram Oxalate | 11 | $137 |
| Divalproex Sodium | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Other acute care in Springfield
- Laura BurpeeSpringfield$1K
- Shannon CarlsonSpringfield$1K
- Cassandra WolaninSpringfield$256
- Kaylie RobertsSpringfield$173
- Robin MillerPortland$74K
- Jacqueline TrussellPortland$15K
- Lina Rossetti-GrulichPortland$8K
- Drury HallBend$5K
- Carla CochranMedford$4K
- Nicole TabbalWilsonville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.